Bimatoprost
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Bimatoprost: From Glaucoma to Alopecia
One-Sentence Summary
Bimatoprost is a synthetic prostamide F2α analogue originally approved for the treatment of ocular hypertension and open-angle glaucoma (Lumigan®), and subsequently approved by the FDA for hypotrichosis of the eyelashes (Latisse®, 2008). The TxGNN model predicts it may be effective for Alopecia (scalp hair loss), with 11 clinical trials and 20 publications currently supporting this direction. Among the 10 predicted indications in this evidence pack, alopecia carries the strongest evidence (L2) and is the only indication with a "Proceed with Guardrails" recommendation — making it the primary focus of this report.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Ocular hypertension / Open-angle glaucoma; eyelash hypotrichosis |
| Predicted New Indication | Alopecia (scalp hair loss) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why Is This Prediction Reasonable?
Bimatoprost acts as a selective prostaglandin FP receptor agonist. When applied to hair follicles, FP receptor activation extends the anagen (active growth) phase of the hair cycle and promotes proliferation of dermal papilla cells — the mesenchymal niche that drives follicle regeneration. Evidence also points to Wnt/β-catenin pathway activation as a secondary mechanism, recruiting quiescent hair follicle stem cells back into the growth cycle.
The mechanistic connection between glaucoma treatment and hair growth was discovered serendipitously. Patients receiving prostaglandin analogues (bimatoprost, latanoprost) for glaucoma were consistently observed to develop periorbital hypertrichosis — darker, longer, and thicker eyelashes. This unwanted side effect was deliberately repurposed into Latisse® (bimatoprost 0.03% ophthalmic solution), which received FDA approval in 2008 for inadequate eyelash growth. The approval established clinical proof-of-concept that the FP receptor pathway can drive hair follicle growth in humans.
The leap to scalp alopecia follows the same mechanistic rationale: if FP receptor activation promotes eyelash follicle cycling, the same receptor system in scalp follicles should, in theory, respond similarly. This hypothesis has been formally tested in at least three large Phase 2 trials (combined n > 850) in androgenetic alopecia, and exploratory work has begun in alopecia areata. The parallel is strikingly analogous to minoxidil — an antihypertensive drug repurposed entirely because patients grew unwanted body hair.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01325337 | Phase 2 | Completed | 307 | Largest male AGA trial — 3 doses of bimatoprost solution vs vehicle and OTC minoxidil 5% (open-label); primary efficacy and safety assessment for scalp hair loss in men |
| NCT01325350 | Phase 2 | Completed | 306 | Female pattern hair loss — 3 doses of bimatoprost vs vehicle and minoxidil 2% (open-label); double-blind design with gender-matched endpoints; mirrors the male trial design |
| NCT01904721 | Phase 2 | Completed | 244 | Second male AGA Phase 2 trial providing independent replication of safety and efficacy data; strengthens confidence in Phase 2-level evidence |
| NCT02170662 | Phase 2 | Completed | 33 | Mechanism-directed trial measuring FP receptor response in androgen-dependent hair follicles; provides biological marker support linking FP receptor density to treatment response |
| NCT05600673 | Phase 1/2 | Completed | 30 | Alopecia areata — combined CO2 fractional laser with bimatoprost 0.03%; evaluated whether bimatoprost enhances hair regrowth when added to laser-assisted drug delivery in immune-mediated hair loss |
| NCT01189279 | Phase 1 | Completed | 42 | Safety, tolerability, and pharmacokinetics of a new bimatoprost scalp formulation; Part 1 tested two formulations, Part 2 tested a third — foundational PK study for scalp-specific formulation development |
| NCT01023841 | Phase 4 | Completed | 71 | Bimatoprost 0.03% once daily for eyelash loss/hypotrichosis in children; extends the safety database to paediatric populations (post-marketing) |
| NCT02848300 | Phase 1 | Completed | 11 | Scalp-specific pharmacokinetics of two bimatoprost formulations over 14 days of once-daily application; quantifies local penetration and systemic exposure levels relevant to safety margin |
| NCT00187577 | N/A | Completed | 14 | Randomised comparison of latanoprost vs bimatoprost ophthalmic solutions for eyelash regrowth in alopecia areata patients; earliest head-to-head evidence in immune-mediated eyelash loss |
| NCT02676310 | Phase 1 | Terminated | 53 | Dose escalation in male AGA — terminated early in 2017; reason for termination (safety signal vs commercial decision) requires clarification before relying on this dataset |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32250713 | 2022 | Systematic Review | J Dermatol Treat | Network meta-analysis of non-surgical AGA monotherapies in men and women; positions bimatoprost within the comparative efficacy landscape relative to minoxidil and finasteride |
| 40252129 | 2025 | RCT/Clinical Study | Arch Dermatol Res | CO2 fractional laser + bimatoprost 0.03% for alopecia areata — evaluates the combination's superiority over laser alone in promoting hair regrowth |
| 29863806 | 2018 | Clinical Guideline | J Dermatol | Japanese clinical guidelines for male- and female-pattern hair loss (2017 version); contextualises bimatoprost within the evidence-based treatment hierarchy for AGA |
| 37089845 | 2023 | Clinical Trial | Indian Dermatol Online J | Bimatoprost vs clobetasol propionate in scalp alopecia areata — prospective non-randomised open-label trial; provides direct comparative data against a standard-of-care topical in AA |
| 35278027 | 2022 | Prospective Study | Dermatol Ther | Topical bimatoprost for eyelash loss in alopecia totalis and universalis; 16 of the enrolled patients showed measurable eyelash regrowth — activity demonstrated in the most severe autoimmune subtypes |
| 28264599 | 2017 | Review | Expert Opin Investig Drugs | Comprehensive review of bimatoprost use across eyelash, eyebrow, and scalp alopecia; synthesises mechanistic rationale and clinical data available through 2017 |
| 29854658 | 2018 | Review | Indian Dermatol Online J | Bimatoprost in dermatology — covers FP receptor mechanism origin story (glaucoma side-effect), pigmentation and hypertrichosis observations, and emerging dermatological applications |
| 33631058 | 2021 | Systematic Review | Dermatol Ther | Systematic review and network meta-analysis of alopecia areata treatments using RCT data; provides comparative ranking context for bimatoprost |
| 35040730 | 2022 | Pharmaceutical Research | Drug Delivery | Novel topical bimatoprost solvent system achieves 4.6-fold higher human skin flux and 529% increase in dermal drug deposition vs ethanol base; demonstrates enhanced AGA efficacy in animal model |
| 37185388 | 2023 | Review | Curr Oncol | Prevention and treatment of chemotherapy-induced alopecia; discusses bimatoprost among emerging agents for CIA, extending the repurposing rationale to oncology-associated hair loss |
New Zealand Market Information
Bimatoprost is currently not marketed in New Zealand. No Medsafe authorisations were identified in this data pull (cutoff: 2026-06-07).
For reference, bimatoprost holds regulatory approval in the following jurisdictions under related indications:
- United States (FDA): Lumigan® (glaucoma/ocular hypertension) and Latisse® (eyelash hypotrichosis), both originator: Allergan/AbbVie
- European Union (EMA): Lumigan® (glaucoma/ocular hypertension)
- Japan (PMDA): Lumigan® (glaucoma/ocular hypertension)
A formal confirmation of New Zealand market status should be sought directly from the Medsafe register, particularly to verify whether any ophthalmic formulations (Lumigan®) are authorised under a different licensee.
Safety Considerations
Detailed Taiwan/New Zealand-specific safety data (warnings, contraindications, and drug interactions) were not retrievable from the sources queried for this report. Please refer to the originator package insert (Lumigan® or Latisse®) for complete safety information.
Based on the drug's pharmacological class and published literature:
- Known class-related adverse effects: Conjunctival hyperaemia and iris pigmentation changes are well-characterised with the ophthalmic formulation; periorbital fat atrophy has been reported with chronic periocular use.
- Relevant to scalp use: Hyperpigmentation at the application site and hypertrichosis beyond the intended area are expected on-mechanism effects — clinically relevant when applied to the scalp or adjacent skin.
- Systemic exposure: Phase 1 scalp PK studies (NCT02848300, NCT01189279) were specifically designed to characterise systemic absorption from topical scalp application; results should be reviewed before clinical use outside of ophthalmic-approved routes.
- No drug-drug interaction data were retrieved in this evidence pack.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Bimatoprost has completed at least three large Phase 2 clinical trials in androgenetic alopecia (combined n > 850 across male and female cohorts), with an established mechanistic rationale directly anchored to its existing FDA-approved eyelash indication. The drug's FP receptor prostamide pathway is pharmacologically validated in human hair follicles, and scalp-specific pharmacokinetic data have been generated. Evidence in alopecia areata is emerging from smaller studies. The main gap is the absence of published Phase 3 efficacy data for scalp AGA and no current New Zealand market authorisation.
To proceed, the following is needed:
- Phase 3 status clarification: Determine whether the bimatoprost AGA development programme (Allergan/AbbVie) was discontinued after Phase 2 or whether Phase 3 data exist but are unpublished; this is the single most important data point for the programme decision.
- Medsafe regulatory pathway assessment: Establish whether a new indication or new formulation (topical scalp solution) requires a full new-entity application or can leverage existing ophthalmic approval dossiers.
- Complete package insert review: Formally retrieve and assess contraindications, special population warnings (pregnancy, paediatrics, renal/hepatic impairment), and ocular risk with inadvertent scalp-to-eye transfer.
- Formulation strategy: Scalp follicles require a penetration-enhanced vehicle to achieve therapeutic follicular concentrations; existing ophthalmic 0.03% solution is unlikely to be directly used — pharmaceutical development work (cf. PMID 35040730, PMID 38577618) should be reviewed.
- Comparative efficacy data: Head-to-head data vs minoxidil (the current standard of care) at Phase 2 level exist; a formal comparative synthesis is needed to quantify the expected benefit over existing therapy before regulatory submission.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.